Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | STS | P08842 | 5/20 | 0.63 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.51 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | ABL1 | P00519 | 1/20 | 0.50 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.50 |
| ▸ | MGLL | Q99685 | 3/20 | 0.49 |
| ▸ | UBE2M | P61081 | 1/20 | 0.49 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23410959 | 1.00 | KMT2A (0.67) | KMT2ASTSPTPN2PTPN1PTPN6 | |
| SCHEMBL23442739 | 0.89 | KMT2A (0.54) | KMT2ASTSGAAMEN1KDM4E | |
| SCHEMBL23411161 | 0.88 | KMT2A (0.76) | KMT2ASTSPTPN2PTPN1PTPN6 | |
| SCHEMBL29967193 | 0.88 | KMT2A (0.76) | KMT2ASTSPTPN2PTPN1PTPN6 | |
| SCHEMBL29157427 | 0.86 | KMT2A (0.80) | KMT2ASTSPTPN2PTPN1PTPN6 | |
| SCHEMBL1651945 | 0.86 | KMT2A (0.80) | KMT2ASTSPTPN2PTPN1PTPN6 | |
| SCHEMBL23411550 | 0.85 | KMT2A (0.65) | KMT2ASTSPTPN2PTPN1PTPN6 | |
| SCHEMBL29967470 | 0.85 | KMT2A (0.65) | KMT2ASTSPTPN2PTPN1PTPN6 | |
| SCHEMBL25172112 | 0.84 | ALDH1A1 (0.58) | KMT2AGAAMEN1KDM4EMGLL | |
| SCHEMBL25767563 | 0.83 | STS (0.52) | KMT2ASTSMEN1KDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12478621-B2 | Substituted aminoquinolones as dgkalpha inhibitors for immune activation | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2025-11-25 | — | — | US | disclosed |
| EP-4065574-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | Bayer Aktiengesellschaft (DE) | 2022-10-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12478621-B2 | Substituted aminoquinolones as dgkalpha inhibitors for immune activation | DGKK, DGKG, DGKA | KMT2A 2132/4885STS 3642/4885PTPN2 2357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.